Premium
A novel anti‐seminoma monoclonal antibody (M2A) labelled with technetium‐99m: potential application for radioimmunoscintigraphy
Author(s) -
Marks A.,
Ballinger J.R.,
Reilly R.M.,
Law J.,
Baumal R.
Publication year - 1995
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1995.tb07316.x
Subject(s) - biodistribution , scintigraphy , technetium , monoclonal antibody , technetium 99m , chemistry , nuclear medicine , radioimmunotherapy , medicine , antibody , pathology , immunology , in vitro , biochemistry
Objective To study the potential usefulness of monoclonal antibody (mAb) M2A specific for seminoma to image tumour nodules in a preclinical nude mouse model. Materials and methods MAb M2A was labelled with technetium‐99m ( 99m Tc) following reduction and was administered intraperitoneally to nude mice bearing subcutaneous HEY cell xenografts against which the antibody was originally raised. Biodistribution and gamma scintigraphy studies were performed 24 h after administration of 99m Tc‐M2A. Results Biodistribution studies showed specific targeting of 99m Tc‐M2A to HEY tumours in comparison with control mAb 99m Tc‐6E8 and 99m Tc‐2G3 which do not bind to HEY cells. Subcutaneous HEY cell tumours (0.5–1.0 g) were successfully imaged using gamma‐scintigraphy following administration of 99m Tc‐M2A. Conclusion The results of this study indicate the potential usefulness of 99m Tc‐M2A as a clinical reagent for imaging seminoma metastases.